Spring Intro 2023

03/03/2023

MRP & DCP ● New active substances ● Known active substances under Article 8(3) ● Generic medicinal products to national (and centralised) authorised reference medicinal products ● Well established use (WEU) (“bibliographic applications”) ● Known active substances in new combination ● Informed consent to national MA ● (Line) extension applications to national authorisations ● Homeopathics, Traditional herbal medicinal products ● Main exclusions – Compulsory Centralised (CP): biotech, NCEs for certain indications, orphan drugs – Products already submitted through CP (unless new dossier)

The Organisation for Professionals in Regulatory Affairs

17

MRP & DCP – finalised procedures

The Organisation for Professionals in Regulatory Affairs

18